Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares stood at 2.2 million during the latest session, with the company’s beta value hitting 1.94. At the last check today, the stock’s price was $1.65, to imply an increase of 3.38% or $0.05 in intraday trading. The PACB share’s 52-week high remains $7.50, putting it -354.55% down since that peak but still an impressive 29.7% since price per share fell to its 52-week low of $1.16. The company has a valuation of $452.97M, with an average of 11.48 million shares in intraday trading volume over the past 10 days and average of 9.91 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Pacific Biosciences of California Inc (PACB), translating to a mean rating of 2.19. Of 11 analyst(s) looking at the stock, 1 analyst(s) give PACB a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.18.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
After registering a 3.38% upside in the latest session, Pacific Biosciences of California Inc (PACB) has traded red over the past five days. The 5-day price performance for the stock is -21.24%, and -19.32% over 30 days. With these gigs, the year-to-date price performance is -9.62%. Short interest in Pacific Biosciences of California Inc (NASDAQ:PACB) saw shorts transact 56.85 million shares and set a 6.69 days time to cover.
The extremes give us $2 and $4 for target low and target high price respectively. As such, PACB has been trading -142.42% off suggested target high and -21.21% from its likely low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Looking at statistics comparing Pacific Biosciences of California Inc share performance against respective industry, we note that the company has outperformed competitors. Pacific Biosciences of California Inc (PACB) shares are -4.67% down over the last 6 months, with its year-to-date growth rate higher than industry average at 18.02% against 15.00%. The rating firms project that company’s revenue will shrink -22.51% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 40.68M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 42.31M.Earnings reports from the last fiscal year show that sales brought in 58.36M and 38.81M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -30.29% before jumping 9.01% in the following quarter.
PACB Dividends
Pacific Biosciences of California Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Pacific Biosciences of California Inc insiders hold 9.31% of total outstanding shares, with institutional holders owning 84.56% of the shares at 93.24% float percentage. In total, 84.56% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 33.21 million shares (or 12.3202% of shares), all amounting to roughly $45.5 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 26.0 million shares, or about 9.6443% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $35.62 million.
We also have ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Pacific Biosciences of California Inc (PACB) shares. Going by data provided on Nov 30, 2024, ARK ETF Tr-ARK Innovation ETF holds roughly 21.32 shares. This is just over 7.78% of the total shares, with a market valuation of $35.5 million. Data from the same date shows that the other fund manager holds a little less at 12.73, or 4.65% of the shares, all valued at about 21.2 million.
